Tanawattanasuntorn Tanotnon, Rattanaburee Thidarath, Thongpanchang Tienthong, Graidist Potchanapond
Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Antioxidants (Basel). 2022 Nov 27;11(12):2347. doi: 10.3390/antiox11122347.
Synthetic -(±)-kusunokinin ((±)KU), a potential anticancer substance, was revealed to have an inhibitory effect on breast cancer. According to the computational modeling prediction, AKR1B1, an oxidative stress and cancer migration protein, could be a target protein of -(-)-kusunokinin. In this study, we determined the binding of (±)KU and AKR1B1 on triple-negative breast and non-serous ovarian cancers. We found that (±)KU exhibited a cytotoxic effect that was significantly stronger than zopolrestat (ZP) and epalrestat (EP) (known AKR1B1 inhibitors) on breast and ovarian cancer cells. (±)KU inhibited aldose reductase activity that was stronger than -(-)-arctiin ((-)AR) but weaker than ZP and EP. Interestingly, (±)KU stabilized AKR1B1 on SKOV3 and Hs578T cells after being heated at 60 and 75 °C, respectively. (±)KU decreased malondialdehyde (MDA), an oxidative stress marker, on Hs578T cells in a dose-dependent manner and the suppression was stronger than EP. Furthermore, (±)KU downregulated AKR1B1 and its downstream proteins, including PKC-δ, NF-κB, AKT, Nrf2, COX2, Twist2 and N-cadherin and up-regulated E-cadherin. (±)KU showed an inhibitory effect on AKR1B1 and its downstream proteins, similar to siRNA-AKR1B1. Interestingly, the combination of siRNA-AKR1B1 with EP or (±)KU showed a greater effect on the suppression of AKR1B1, N-cadherin, E-cadherin and NF-κB than single treatments. Taken together, we concluded that (±)KU-bound AKR1B1 leads to the attenuation of cellular oxidative stress, as well as the aggressiveness of breast cancer cell migration.
合成的(±)-库索诺基宁((±)KU)是一种潜在的抗癌物质,已被发现对乳腺癌具有抑制作用。根据计算模型预测,氧化应激和癌症迁移蛋白AKR1B1可能是-(-)-库索诺基宁的靶蛋白。在本研究中,我们确定了(±)KU与AKR1B1在三阴性乳腺癌和非浆液性卵巢癌中的结合情况。我们发现,(±)KU对乳腺癌和卵巢癌细胞表现出比唑泊司他(ZP)和依帕司他(EP)(已知的AKR1B1抑制剂)显著更强的细胞毒性作用。(±)KU抑制醛糖还原酶活性的能力强于-(-)-牛蒡子苷((-)AR),但弱于ZP和EP。有趣的是,(±)KU分别在60℃和75℃加热后,能使SKOV3和Hs578T细胞中的AKR1B1稳定。(±)KU以剂量依赖的方式降低了Hs578T细胞中氧化应激标志物丙二醛(MDA)的水平,且抑制作用强于EP。此外,(±)KU下调了AKR1B1及其下游蛋白,包括蛋白激酶C-δ(PKC-δ)、核因子κB(NF-κB)、蛋白激酶B(AKT)、核因子E2相关因子2(Nrf2)、环氧化酶2(COX2)、Twist2和N-钙黏蛋白,并上调了E-钙黏蛋白。(±)KU对AKR1B1及其下游蛋白表现出抑制作用,类似于小干扰RNA-AKR1B1(siRNA-AKR1B1)。有趣的是,siRNA-AKR1B1与EP或(±)KU联合使用对AKR1B1、N-钙黏蛋白、E-钙黏蛋白和NF-κB的抑制作用比单一处理更强。综上所述,我们得出结论,(±)KU与AKR1B1结合可导致细胞氧化应激减轻,以及乳腺癌细胞迁移侵袭性减弱。